Highlights from the ERS Congress 2024
During the recent European Respiratory Society (ERS) Congress, Pulmonx Corporation, a leader in innovative treatments for severe lung diseases, presented vital clinical findings from the AeriSeal® CONVERT trial along with long-term results from the LIBERATE study. These presentations underscore the company’s dedication to improving the quality of life for patients dealing with chronic conditions such as chronic obstructive pulmonary disease (COPD) and emphysema.
AeriSeal CONVERT Trial: A New Hope
A key focus of the presentations was the AeriSeal CONVERT trial, which explored the effectiveness of the AeriSeal System, specifically designed for patients facing collateral ventilation issues. Professor Kaid Darwiche provided insights into how the trial allowed individuals who were previously considered ineligible for treatment to benefit, showcasing the system’s adaptability.
Key Findings from the CONVERT Trial
The results revealed that an impressive 77.6% of patients identified with collateral ventilation transitioned to a collateral ventilatory negative state following treatment with the AeriSeal System. The post-treatment improvements were statistically significant:
- Average lung function showed an increase of 80 mL or 10.2%, as measured by Forced Expiratory Volume in 1 second (FEV1).
- Quality of life scores improved by 6.3 points according to St. George’s Respiratory Questionnaire metrics.
- At the 45-day mark, a reduction of over one liter in treated lobe volume was observed.
- 89% of patients who converted achieved a minimal clinically important difference of at least 350 mL in lobe volume reduction six months after valve treatment.
These promising results position the AeriSeal System as a groundbreaking option for patients with collateral ventilation, allowing them to benefit from bronchoscopic lung volume reduction facilitated by Zephyr Valves.
Durability Demonstrated in LIBERATE Study
The second part of the presentation highlighted long-term outcomes from the LIBERATE study, where Professor Gerard Criner emphasized the lasting benefits of Zephyr Valves. The data demonstrated that patients who received valve treatment experienced sustained improvements in lung function for at least five years:
Five-Year Outcomes
- Annual lung function improvements varied from 109 mL in the first year to 79 mL by the fifth year, indicating a solid safety profile.
- In contrast to traditional medical treatments, which typically see a decline in lung function, the FEV1 readings showed significant advantages.
- No increase in respiratory adverse events was noted from years two to five, indicating prolonged effectiveness and patient tolerance.
- The mortality rate among participants was 38% over five years, significantly lower than the 49% observed in historically managed control subjects.
These findings from the LIBERATE study suggest that Zephyr Valves continue to offer significant long-term benefits for those struggling with severe emphysema.
Future Perspectives
Steve Williamson, President and CEO of Pulmonx, expressed his excitement about these findings, emphasizing a commitment to developing treatments that can improve patient outcomes. He mentioned ongoing efforts to advance to the next phase of clinical trials, specifically the CONVERT II pivotal trial, which aims to enroll around 200 patients to validate the effectiveness of the AeriSeal System in conjunction with Zephyr Valves.
AeriSeal’s Breakthrough Status
Importantly, the AeriSeal System has received Breakthrough Device designation from the FDA, designed to enhance lung function by disrupting collateral ventilation. This advancement opens up new possibilities for effective treatments in severe COPD cases. The ongoing studies and updates presented at the ERS Congress highlight Pulmonx's promising path toward transforming care for patients with complex respiratory conditions.
About Pulmonx Corporation
Founded with a vision to innovate in lung care, Pulmonx Corporation (NASDAQ: LUNG) is recognized globally for its efforts in providing minimally invasive treatment options for COPD and severe emphysema. The company is dedicated to delivering solutions that not only enhance lung function but also significantly improve patients' quality of life. Their leading products include the Zephyr Endobronchial Valves, Chartis Pulmonary Assessment System, and the StratX Lung Analysis Platform.
Frequently Asked Questions
What were the key highlights presented at the ERS Congress 2024?
Pulmonx showcased the effectiveness of the AeriSeal System and the long-term benefits of Zephyr Valves in treating severe lung diseases.
What was the success rate of the AeriSeal System in the CONVERT trial?
The AeriSeal System achieved a 77.6% conversion rate in patients previously classified as collateral ventilation positive.
How long did the benefits of Zephyr Valves last, according to the LIBERATE study?
Patients exhibited durable lung function improvements lasting at least five years.
What is the purpose of the upcoming CONVERT II trial?
The CONVERT II trial aims to further evaluate the safety and effectiveness of the AeriSeal System, with plans to enroll approximately 200 patients.
Who leads Pulmonx Corporation?
Steve Williamson serves as the President and CEO, steering Pulmonx in its mission to enhance treatment options for severe lung diseases.
